
Bristol Myers Squibb company profile
$63.43+1.78%Close 13 Nov 2026 · Market value $128.5B
About Bristol Myers Squibb
Bristol Myers Squibb is a biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes and sells medicines for serious diseases, operating in a single segment. Its focus areas include oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. Its marketed products include Opdivo, Eliquis, Breyanzi, Abecma, Reblozyl, Camzyos, Cobenfy and Sotyktu, among others, spanning small molecule drugs, biologics, CAR-T cell therapies and other modalities. The company sells its products worldwide, principally to wholesalers, distributors and specialty pharmacies, and to a lesser extent to retailers, hospitals, clinics, government agencies and patients directly. Significant manufacturing operations are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland.
A summary of the business section of the company's latest annual report, filed 11 Feb 2026.
Company facts
| Ticker | BMY · NYSE |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Pharmaceuticals |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 14272 |
|---|
| Latest annual report | 10-K, filed 11 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| D. V. Elkins | EVP, Chief Financial Officer | 190K | Open-market sale, 1 Apr 2026 |
|---|
| J. Haller, M.D. | Director | 135K | Open-market sale, 5 Nov 2026 |
|---|
| S. Hirawat, M.D. | EVP,Chief Med.Offr.,Drug Dev. | 31.9K | Open-market purchase, 25 Apr 2025 |
|---|
| A. Lenkowsky | EVP, Chief Commercial Officer | 29.3K | Code J, 1 May 2026 |
|---|
| C. Massacesi, M.D. | EVP,Chief Med Offr,Head of Dev | 0 | Open-market sale, 9 Sep 2026 |
|---|
| Shanahan Karin | EVP, Chief Supply Chain & Ops | — | Option exercise, 1 Nov 2026 |
|---|
| Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | — | Option exercise, 1 Nov 2026 |
|---|
| BOERNER CHRISTOPHER S. | Chief Executive Officer · Director | — | Option exercise, 1 Nov 2026 |
|---|
| Gallman Cari | EVP, General Counsel | — | Option exercise, 2 Oct 2026 |
|---|
| Short Bartie Wendy | EVP, Corporate Affairs | — | Option exercise, 1 Sep 2026 |
|---|
| Holzer Phil M | SVP and Controller | — | Open-market sale, 25 Aug 2026 |
|---|
| Hoch Lynelle | President, Cell Therapy Org. | — | Option exercise, 10 Mar 2026 |
|---|
| Poole Ahn Amanda | EVP, Chief People Officer | — | Code J, 10 Mar 2026 |
|---|
| Plenge Robert M | EVP, Chief Research Officer | — | Shares withheld for tax, 10 Mar 2026 |
|---|
| Hickey Benjamin | President, RayzeBio Org. | — | Option exercise, 27 Feb 2026 |
|---|
| LEUNG SANDRA | EVP, General Counsel | — | Shares withheld for tax, 10 Mar 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
BMY in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.